Huntsman Cancer Institute ( Site 0004)

Salt Lake City, Utah 84112

0 studies enrolling now · 3 studies all time

What they study most

Head and Neck Squamous Cell Carcinoma (HNSCC), Lymphoma, Neoplasm Metastasis, Solid Tumors

Studies at this site

• Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) — Completed
• Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) — Completed
• A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) — Stopped early